Premature babies in incubators, patients with acute respiratory failure in intensive care, or COPD patients at home: they all suffer from the same, potentially fatal condition: hypercapnia = an elevated CO2 level in the blood.

We are talking about 43 million patients worldwide.

Hypercapnia is one of the major, so far inadequately solved challenges in the intensive care treatment of acute respiratory failure and during prolonged weaning after long-term ventilation as well as in the outpatient treatment of chronic obstructive pulmonary disease (COPD).

Our goal is to revolutionize therapy and significantly improve the survival and, above all, the quality of life of these large patient groups suffering from hypercapnia.

Instead of addressing the problem through the lungs, RESPILIQ™ uses the human intestine as a respiratory organ. The human intestine forms a highly effective CO2 exchange membrane. In the intestine, RESPILIQ™ can bind CO2 from intestinal fluid and excrete it naturally. Administered orally or rectally, RESPILIQ™ thus initiates a life-saving reduction of CO2 in the blood.